compounded semaglutide weight loss for Women Compounded Semaglutide (GLP-1) - 4th

Virtual Telemed Weight Loss Program FAQs Have additional questions

Zepbound (tirzepatide): Patients on the 15 mg dose lost an average of 21% of their body weight over 72 weeks

This direct molecular targeting underpins their utility as specific anti-cancer agents

It is primarily approved for the treatment of type 2 diabetes

Limited information has been reported on long-term side effects and potential risk of cancer associated with use, so patients should weigh their benefit from taking this medication against possible risks before starting semaglutide therapy

The co-primary endpoints follow the FDA's established framework for obesity drugs: mean percent change in body weight from baseline and the proportion of participants achieving at least 5% body weight reduction